Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 9 February 2009, doi:10.1136/bmj.b550
Cite this as: BMJ 2009;338:b550
Rebecca Coombes
1 London
| The first 150 words of the full text of this article appear below. |
Critics have questioned the ethics of carrying out screening for dementia, part of the work proposed for a new network of memory clinics in England and Wales, when evidence of the effectiveness of current drugs for the disease is limited.
Iain Chalmers, editor of the James Lind Library and formerly of the Cochrane Collaboration, speaking at a Lancet conference in London last week, said that he was sceptical about the clinics.
"People ask why NICE [the National Institute for Health and Clinical Excellence] is limiting access to Alzheimers drugs. Well, the costs are rising very fast and they are not fantastically good. We are going to all have these memory clinics but what do we do when we diagnose someone?" he said. "I heard one expert say: The cupboard is bare. Cholinesterase inhibitors cost £70m [
80m; $100m] a year. You could have at least 700 extra elderly care doctors
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses